Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 11, 2014, Pages 2556-2562

  Sajjad, Amna ^a,b   Novoyatleva, Tatyana ^a,e   Vergarajauregui, Silvia ^c   Troidl, Christian ^d   Schermuly, Ralph T ^e   Tucker, Haley O ^f   Engel, Felix B ^c  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Kerckhoff Heart and Thorax Center   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Apoptosis; Cardiomyocyte; Heart failure; P53; Smyd2

Indexed keywords

COBALT CHLORIDE; HEAT SHOCK PROTEIN 90; LYSINE METHYLTRANSFERASE SMYD2; METHYLTRANSFERASE; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; GENE SILENCING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT;

EID: 84905393801     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.06.019     Document Type: Article

References (31)

1. Mughal W., Dhingra R., Kirshenbaum L.A. Striking a balance: autophagy, apoptosis, and necrosis in a normal and failing heart. Curr. Hypertens. Rep. 2012, 14:540-547. 10.1007/s11906-012-0304-5.
2. Wang L., Li L., Zhang H., Luo X., Dai J., Zhou S., Gu J., Zhu J., Atadja P., Lu C., Li E., Zhao K. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. J. Biol. Chem. 2011, 286:38725-38737. 10.1074/jbc.M111.262410.
3. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632. 10.1038/nature05287.
4. Cheng X., Collins R.E., Zhang X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 2005, 34:267-294. 10.1146/annurev.biophys.34.040204.144452.
5. Abu-Farha M., Lanouette S., Elisma F., Tremblay V., Butson J., Figeys D., Couture J.F. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. J. Mol. Cell Biol. 2011, 3:301-308. 10.1093/jmcb/mjr025.
6. Brown M.A., Sims R.J., Gottlieb P.D., Tucker P.W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 2006, 5:26. 10.1186/1476-4598-5-26.
7. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6:731-740. 10.1038/ncb1151.
8. Saddic L.A., West L.E., Aslanian A., Yates J.R., Rubin S.M., Gozani O., Sage J. Methylation of the retinoblastoma tumor suppressor by SMYD2. J. Biol. Chem. 2010, 285:37733-37740. 10.1074/jbc.M110.137612.
9. Donlin L.T., Andresen C., Just S., Rudensky E., Pappas C.T., Kruger M., Jacobs E.Y., Unger A., Zieseniss A., Dobenecker M.W., Voelkel T., Chait B.T., Gregorio C.C., Rottbauer W., Tarakhovsky A., Linke W.A. Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization. Genes Dev. 2012, 26:114-119. 10.1101/gad.177758.111.
10. Zhang X., Tanaka K., Yan J., Li J., Peng D., Jiang Y., Yang Z., Barton M.C., Wen H., Shi X. Regulation of estrogen receptor alpha by histone methyltransferase SMYD2-mediated protein methylation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17284-17289. 10.1073/pnas.1307959110.
11. Gottlieb P.D., Pierce S.A., Sims R.J., Yamagishi H., Weihe E.K., Harriss J.V., Maika S.D., Kuziel W.A., King H.L., Olson E.N., Nakagawa O., Srivastava D. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat. Genet. 2002, 31:25-32. 10.1038/ng866.
12. Tan X., Rotllant J., Li H., De Deyne P., Du S.J. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2713-2718. 10.1073/pnas.0509503103.
13. Voelkel T., Andresen C., Unger A., Just S., Rottbauer W., Linke W.A. Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function. Biochim. Biophys. Acta 2013, 1833:812-822. 10.1016/j.bbamcr.2012.09.012.
14. Diehl F., Brown M.A., van Amerongen M.J., Novoyatleva T., Wietelmann A., Harriss J., Ferrazzi F., Bottger T., Harvey R.P., Tucker P.W., Engel F.B. Cardiac deletion of Smyd2 is dispensable for mouse heart development. PLoS One 2010, 5:e9748. 10.1371/journal.pone.0009748.
15. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., Akazawa H., Tateno K., Kayama Y., Harada M., Shimizu I., Asahara T., Hamada H., Tomita S., Molkentin J.D., Zou Y., Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448. 10.1038/nature05602.
16. Mollmann H., Nef H.M., Kostin S., von Kalle C., Pilz I., Weber M., Schaper J., Hamm C.W., Elsasser A. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc. Res. 2006, 71:661-671. 10.1016/j.cardiores.2006.06.013.
17. Engel F.B., Hauck L., Cardoso M.C., Leonhardt H., Dietz R., von Harsdorf R. A mammalian myocardial cell-free system to study cell cycle reentry in terminally differentiated cardiomyocytes. Circ. Res. 1999, 85:294-301. 10.1161/01.RES.85.3.294.
18. Gresch O., Engel F.B., Nesic D., Tran T.T., England H.M., Hickman E.S., Korner I., Gan L., Chen S., Castro-Obregon S., Hammermann R., Wolf J., Muller-Hartmann H., Nix M., Siebenkotten G., Kraus G., Lun K. New non-viral method for gene transfer into primary cells. Methods 2004, 33:151-163. 10.1016/j.ymeth.2003.11.009.
19. Naito A.T., Okada S., Minamino T., Iwanaga K., Liu M.L., Sumida T., Nomura S., Sahara N., Mizoroki T., Takashima A., Akazawa H., Nagai T., Shiojima I., Komuro I. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ. Res. 2010, 106:1692-1702. 10.1161/CIRCRESAHA.109.214346.
20. D'Amours D., Desnoyers S., D'Silva I., Poirier G.G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 1999, 342(Pt 2):249-268.
21. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24. 10.1016/j.molcel.2010.06.017.
22. Hong D.S., Banerji U., Tavana B., George G.C., Aaron J., Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat. Rev. 2013, 39:375-387. 10.1016/j.ctrv.2012.10.001.
23. Djurovic S., Iversen N., Jeansson S., Hoover F., Christensen G. Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes. Mol. Biotechnol. 2004, 28:21-32.
24. Long X., Boluyt M.O., Hipolito M.L., Lundberg M.S., Zheng J.S., O'Neill L., Cirielli C., Lakatta E.G., Crow M.T. p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J. Clin. Invest. 1997, 99:2635-2643. 10.1172/JCI119452.
25. Cesselli D., Jakoniuk I., Barlucchi L., Beltrami A.P., Hintze T.H., Nadal-Ginard B., Kajstura J., Leri A., Anversa P. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ. Res. 2001, 89:279-286. 10.1161/hh1501.094115.
26. Leri A., Claudio P.P., Li Q., Wang X., Reiss K., Wang S., Malhotra A., Kajstura J., Anversa P. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J. Clin. Invest. 1998, 101:1326-1342. 10.1172/JCI316.
27. Shizukuda Y., Matoba S., Mian O.Y., Nguyen T., Hwang P.M. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol. Cell. Biochem. 2005, 273:25-32.
28. Toth A., Jeffers J.R., Nickson P., Min J.Y., Morgan J.P., Zambetti G.P., Erhardt P. Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H52-H60. 10.1152/ajpheart.01046.2005.
29. Xiong S., Van Pelt C.S., Elizondo-Fraire A.C., Fernandez-Garcia B., Lozano G. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 2007, 115:2925-2930. 10.1161/CIRCULATIONAHA.107.689901.
30. Zhu W., Soonpaa M.H., Chen H., Shen W., Payne R.M., Liechty E.A., Caldwell R.L., Shou W., Field L.J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119:99-106. 10.1161/CIRCULATIONAHA.108.799700.
31. Abu-Farha M., Lambert J.P., Al-Madhoun A.S., Elisma F., Skerjanc I.S., Figeys D. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics 2008, 7:560-572. 10.1074/mcp.M700271-MCP200.